The estrogenic component of estro- progestin (EP) is responsible for a negative impact on the metabolic and lipid assessment in women with polycystic ovary syndrome (PCOS).
Romualdi, D., De Cicco, S., Busacca, M., Gagliano, D., Lanzone, A., Guido, M., Clinical efficacy and metabolic impact of two different dosages of ethinyl-estradiol in association with drospirenone in normal-weight women with polycystic ovary syndrome: a randomized study, <<JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION>>, 2013; 36 (8): 636-641. [doi:10.1007/BF03346756] [http://hdl.handle.net/10807/53435]
Clinical efficacy and metabolic impact of two different dosages of ethinyl-estradiol in association with drospirenone in normal-weight women with polycystic ovary syndrome: a randomized study
Romualdi, Daniela;De Cicco, Simona;Lanzone, Antonio;Guido, Maurizio
2013
Abstract
The estrogenic component of estro- progestin (EP) is responsible for a negative impact on the metabolic and lipid assessment in women with polycystic ovary syndrome (PCOS).
File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
